Ciprofloxacin and Norfloxacin Hybrid Compounds: Potential Anticancer Agents

Chhikara, B.S.; Parang, K. Chemical biology letters global cancer statistics 2022: The trends projection analysis. Chem. Biol. Lett, 2022, 10, 451.

Tzenios, P.N. Obesity as a risk factor for different types of cancer. EPRA Int. J. Res. Dev, 2023, 8, 97-100.

Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48.
[http://dx.doi.org/10.3322/caac.21763] [PMID: 36633525]

Collatuzzo, G.; Santucci, C.; Malvezzi, M.; La Vecchia, C.; Boffetta, P.; Negri, E. Trends in gastric cancer mortality 1990–2019 in 36 countries worldwide, with predictions to 2025, and incidence, overall and by subtype. Cancer Med., 2023, 12(8), 9912-9925.
[http://dx.doi.org/10.1002/cam4.5685] [PMID: 36815614]

Luo, G.; Zhang, Y.; Etxeberria, J.; Arnold, M.; Cai, X.; Hao, Y.; Zou, H. Projections of lung cancer incidence by 2035 in 40 Countries Worldwide: Population-based study. JMIR Public Health Surveill., 2023, 9, e43651.
[http://dx.doi.org/10.2196/43651] [PMID: 36800235]

Berenguer, C.V.; Pereira, F.; Câmara, J.S.; Pereira, J.A.M. Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. Curr. Oncol., 2023, 30(2), 2300-2321.
[http://dx.doi.org/10.3390/curroncol30020178] [PMID: 36826139]

AbuBaih, R.; Fawzy, M.; Nazmy, M. The prospective potential of fluoroquinolones as anticancer agents. J. Modern Res., 2023, 5(1), 4-10.
[http://dx.doi.org/10.21608/jmr.2022.166535.1094]

Kloskowski, T.; Frąckowiak, S.; Adamowicz, J.; Szeliski, K.; Rasmus, M.; Drewa, T.; Pokrywczyńska, M. Quinolones as a potential drug in genitourinary cancer treatment-A literature review. Front. Oncol., 2022, 12, 890337.
[http://dx.doi.org/10.3389/fonc.2022.890337] [PMID: 35756639]

Telfah, A.; Abu Shari’ah, N.; Ababneh, R.; Bahti, A.; Al-Akhras, M.A.; Al-Hiari, Y.; Jum’h, I.; Abu-Dahab, R.; Telfah, M.; Al Bataineh, Q.M.; Hergenröder, R. 1H-NMR analysis of fluoroquinolone (pyridopyrrole quinoxaline, PPQ) conjugated to gold nanoparticles for synergistic anticancer drug design. J. Mol. Struct., 2023, 1292, 136081.
[http://dx.doi.org/10.1016/j.molstruc.2023.136081]

Kloskowski, T.; Fekner, Z.; Szeliski, K.; Paradowska, M.; Balcerczyk, D.; Rasmus, M.; Dąbrowski, P.; Kaźmierski, Ł.; Drewa, T.; Pokrywczyńska, M. Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures. Front. Oncol., 2023, 13, 1222411.
[http://dx.doi.org/10.3389/fonc.2023.1222411] [PMID: 37534254]

Elanany, M.A.; Osman, E.E.A.; Gedawy, E.M.; Abou-Seri, S.M. Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis. Sci. Rep., 2023, 13(1), 4144.
[http://dx.doi.org/10.1038/s41598-023-30885-5] [PMID: 36914702]

Bento, C.M.; Silva, A.T.; Mansano, B.; Aguiar, L.; Teixeira, C.; Gomes, M.S.; Gomes, P.; Silva, T.; Ferraz, R. Improving the antimycobacterial drug clofazimine through formation of organic salts by combination with fluoroquinolones. Int. J. Mol. Sci., 2023, 24(2), 1402.
[http://dx.doi.org/10.3390/ijms24021402] [PMID: 36674923]

Pretali, L.; Fasani, E.; Sturini, M. Current advances on the photocatalytic degradation of fluoroquinolones: photoreaction mechanism and environmental application. Photochem. Photobiol. Sci., 2022, 21(5), 899-912.
[http://dx.doi.org/10.1007/s43630-022-00217-z] [PMID: 35416639]

Suaifan, G.A.R.Y.; Mohammed, A.A.M.; Alkhawaja, B.A. Fluoroquinolones’ biological activities against laboratory microbes and cancer cell lines. Molecules, 2022, 27(5), 1658.
[http://dx.doi.org/10.3390/molecules27051658] [PMID: 35268759]

Schmid, K.L. Fluoroquinolones are a potent form of chemotherapy. Clin. Exp. Optom., 2021, 104(3), 412-416.
[http://dx.doi.org/10.1111/cxo.13102] [PMID: 32484262]

Abdel-Rahman, I. M.; Mustafa, M.; Mohamed, S. A.; Yahia, R.; Abdel-Aziz, M.; Abuo-Rahma, G. E. A.; Hayallah, A. M. Novel Mannich bases of ciprofloxacin with improved physicochemical properties, antibacterial, anticancer activities and caspase-3 mediated apoptosis. Bioorg. Chem., 2021, 107, 104629.
[http://dx.doi.org/10.1016/j.bioorg.2021.104629]

Kassab, A.E.; Gedawy, E.M. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity. Eur. J. Med. Chem., 2018, 150, 403-418.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.026] [PMID: 29547830]

Yadav, V.; Talwar, P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomed. Pharmacother., 2019, 111, 934-946.
[http://dx.doi.org/10.1016/j.biopha.2018.12.119] [PMID: 30841473]

Abdel-Aal, M.A.A.; Abdel-Aziz, S.A.; Shaykoon, M.S.A.; Abuo-Rahma, G.E.D.A. Towards anticancer fluoroquinolones: A review article. Arch. Pharm., 2019, 352(7), 1800376.
[http://dx.doi.org/10.1002/ardp.201800376] [PMID: 31215674]

Ahadi, H.; Emami, S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: Synthesis and in vitro studies. Eur. J. Med. Chem., 2020, 187, 111970.
[http://dx.doi.org/10.1016/j.ejmech.2019.111970] [PMID: 31881454]

Yang, P.; Luo, J.B.; Wang, Z.Z.; Zhang, L.L.; Feng, J.; Xie, X.B.; Shi, Q.S.; Zhang, X.G. Synthesis, molecular docking, and evaluation of antibacterial activity of 1,2,4-triazole-norfloxacin hybrids. Bioorg. Chem., 2021, 115, 105270.
[http://dx.doi.org/10.1016/j.bioorg.2021.105270] [PMID: 34467939]

Szumilak, M.; Wiktorowska-Owczarek, A.; Stanczak, A. Hybrid drugs-A strategy for overcoming anticancer drug resistance? Molecules, 2021, 26(9), 2601.
[http://dx.doi.org/10.3390/molecules26092601] [PMID: 33946916]

Singh, A.K.; Kumar, A.; Singh, H.; Sonawane, P.; Paliwal, H.; Thareja, S.; Pathak, P.; Grishina, M.; Jaremko, M.; Emwas, A.H.; Yadav, J.P.; Verma, A.; Khalilullah, H.; Kumar, P. Concept of hybrid drugs and recent advancements in anticancer hybrids. Pharmaceuticals, 2022, 15(9), 1071.
[http://dx.doi.org/10.3390/ph15091071] [PMID: 36145292]

Alkhzem, A.H.; Woodman, T.J.; Blagbrough, I.S. Design and synthesis of hybrid compounds as novel drugs and medicines. RSC Advances, 2022, 12(30), 19470-19484.
[http://dx.doi.org/10.1039/D2RA03281C] [PMID: 35865575]

Dallavalle, S.; Dobričić, V.; Lazzarato, L.; Gazzano, E.; Machuqueiro, M.; Pajeva, I.; Tsakovska, I.; Zidar, N.; Fruttero, R. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist. Updat., 2020, 50, 100682.
[http://dx.doi.org/10.1016/j.drup.2020.100682] [PMID: 32087558]

Fortin, S.; Bérubé, G. Advances in the development of hybrid anticancer drugs. Expert Opin. Drug Discov., 2013, 8(8), 1029-1047.
[http://dx.doi.org/10.1517/17460441.2013.798296] [PMID: 23646979]

Etebu, E.; Arikekpar, I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. Int. J. Appl. Microbiol. Biotechnol. Res, 2016, 4, 90-101.

O’Rourke, A.; Beyhan, S.; Choi, Y.; Morales, P.; Chan, A.P.; Espinoza, J.L.; Dupont, C.L.; Meyer, K.J.; Spoering, A.; Lewis, K.; Nierman, W.C.; Nelson, K.E. Mechanism-of-action classification of antibiotics by global transcriptome profiling. Antimicrob. Agents Chemother., 2020, 64(3), e01207-19.
[http://dx.doi.org/10.1128/AAC.01207-19] [PMID: 31907190]

Hsia, Y.; Lee, B.R.; Versporten, A.; Yang, Y.; Bielicki, J.; Jackson, C.; Newland, J.; Goossens, H.; Magrini, N.; Sharland, M.; Irwin, A.; Akula, A.; Bamford, A.; Chang, A.; da Silva, A.; Whitelaw, A.; Dramowski, A.; Vasudevan, A.K.; Sharma, A.; Justicia, A.; Chikkappa, A.; Slowinska-Jarzabek, B.; Rippberger, B.; Zhao, C.; Tersigni, C.; Cheng, C.; Harkensee, C.; Jing, C.; Zhu, C.; Li, C.; Tagliabue, C.; Epalza, C.; Jacqueline, D.; Tian, D.; Jinka, D.; Gkentzi, D.; Dharmapalan, D.; Benadof, D.; Papadimitriou, E.; Iosifidis, E.; Roilides, E.; Yarci, E.; Majda-Stanisławska, E.; Gowin, E.; Chappell, F.; Torres, F.M.; Collett-White, F.; Liu, G.; Lu, G.; Syrogiannopoulos, G.; Pitsava, G.; Alvarez-Uria, G.; Renk, H.; Mahmood, H.; Saxen, H.; Finlayson, H.; Green, H.; Rabie, H.; Kandraju, H.; Zhang, H.; Okokon, I.; Cross, J.; Herberg, J.; Li, J.; Zhang, J.; Deng, J.; Liu, J.; Qian, J.; Yang, J.; Sicińska, J.; Hübner, J.; Fukuoka, K.; Yao, K.; Cheung, K.; Ojeda, K.; Kaffe, K.; Kreitmeyer, K.; Doerholt, K.; Grimwood, K.; Ledoare, K.; Vazouras, K.; Shen, K.; Tang, L.; Zhang, L.; Lin, L.; Ashkenazi-Hoffnung, L.; Wu, L.; Wang, L.; Teston, L.; Galli, L.; Speirs, L.; Tsolia, M.; Hufnagel, M.; Knuf, M.; Duse, M.; Ding, M.; Rozic, M.; Premru, M.; O’Connell, N.; Rieber, N.; Spyridis, N.; Tunga, O.; Conejo, P.R.; McMaster, P.; Lumbiganon, P.; Pansa, P.; D’Argenio, P.; Moriarty, P.; Nikolic, P.; Wang, P.; Paopongsawan, P.; Cao, Q.; Deng, Q.; Laxminarayan, R.; Kanithi, R.; Jimenez, R.; Cao, S.; Singh, S.; Rees, S.; Praveen, S.; Kekomaki, S.; Hackett, S.; Ashkenazi, S.; Chang, S.M.; Drysdale, S.; Koning, S.; Subramanian, S.; Murki, S.; Vergnano, S.; Gandra, S.; Esposito, S.; Anugulruengkitt, S.; Puthanakit, T.; Behrends, U.; Papaevangelous, V.; Jian, V.; Li, W.; Zhao, W.; Wang, W.; Zhang, W.; Mu, X.; Dong, X.; Jiang, X.; Chen, X.; Wang, Y.; Zheng, Y.; Horikoshi, Y.; Aboderin, A.; Olayinka, A.; Dedeic-Ljubovic, A.; McCorry, A.; Enimil, A.; Neubert, A.; solano; Pignatari, A.; Poojary, A.; Kambaralieva, B.; McCullagh, B.; Carevi, B.; Van Herendael, B.; Gormley, C.; Carvajal, C.; Ramírez, C.; Fitzgerald, D.; Sabuda, D.; Konopnicki, D.; Lacej, D.; Pierard, D.; Rios, E.; Marshall, E.; Firre, E.; van Elzakker, E.; Shaqiri, E.; Darwish Elhajji, F.; Gawrys, G.; Markovic, G.; Kunsihima, H.; Chen, H.H.; Sviestina, I.; Pristas, I.; Hoxha, I.; Korinteli, I.; Mareković, I.; Soltani, J.; Labarca, J.; AlSalman, J.; Horvatic, J.; Frimpong, J.A.; Pagava, K.; Kei, K.; Okinaka, K.; Iregbu, K.; Ghazaryan, L.; Raka, L.; Gessner-Wharton, M.; Aldeyab, M.; Cooper, M.; del Castillo, M.; Hojman, M.; Hudson, M.; Alshehri, M.; Ling, M.L.; Greer, N.; Oduyebo, O.; Buijtels, P.; Terol Barrero, P.; Zarb, P.; Schelstraete, P.E.; Nwajiobi-Princewill, P.I.P.; Khanna, P.; Quiros, R.; Simovic, S.; Thompson, S.; Chan, S.M.; Burokiene, S.; Drysdale, S.; Rachina, S.; Usonis, V.; Cornistein, W.; Holemans, X.; Gu, Y.; Brothers, A.; Hersh, A.; Fernandez, A.; Tribble, A.; Hurst, A.; Green, A.; Hammer, B.; Lee, B.P.; Kuzmic, B.; Shapiro, C.; Boge, C.; Haslam, D.; Berman, D.; Naeem, F.; Johnson, G.; Schwenk, H.; Orr, H.; Maples, H.; Olsen, J.; Gerber, J.; Girotto, J.; Zweiner, J.; Goldman, J.; Gillon, J.; Tansmore, J.; Manaloor, J.; Courter, J.; Mongkolrattanothai, K.; Patel, K.; Merkel, K.; Namtu, K.; Flett, K.; Lee, K.; Nichols, K.; Klein, K.; Handy, L.; Castagnini, L.; Mazade, M.; Heger, M.; Fernandez, M.; Chang, M.; Crawford, M.; Nelson, M.; Bennett, N.; Jaggi, P.; Hamdy, R.; Banerjee, R.; Olivero, R.; Patel, S.; Arnold, S.; Ogrin, S.; Jones, S.; Parker, S.; Kubes, S.; Hymes, S.; Weissman, S.; Chan, S.; Henderson, S.; Metjian, T. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries. Lancet Glob. Health, 2019, 7(7), e861-e871.
[http://dx.doi.org/10.1016/S2214-109X(19)30071-3]

Alshareef, H.; Alanazi, A.; Alatawi, N.; Eleshmawy, N.; Ali, M. Assessment of antibiotic prescribing patterns at dental and primary health care clinics according to WHO Access, Watch, Reserve (AWaRe) classification. Am. J. Infect. Control, 2023, 51(3), 289-294.
[http://dx.doi.org/10.1016/j.ajic.2022.07.009] [PMID: 35870657]

Chae, J.; Kim, B.; Kim, D.S. Changes in antibiotic consumption patterns after the implementation of the National Action Plan according to the Access, Watch, Reserve (AWaRe) classification system. Int. J. Infect. Dis., 2022, 122, 345-351.
[http://dx.doi.org/10.1016/j.ijid.2022.06.013] [PMID: 35705118]

Sharma, P.C.; Goyal, R.; Sharma, A.; Sharma, D.; Saini, N.; Rajak, H.; Sharma, S.; Thakur, V.K. Insights on fluoroquinolones in cancer therapy: Chemistry and recent developments. Mater. Today Chem., 2020, 17, 100296.
[http://dx.doi.org/10.1016/j.mtchem.2020.100296]

Khwaza, V.; Oyedeji, O.O.; Oselusi, S.O.; Morifi, E.; Nwamadi, M.; Tantoh Ndinteh, D.; Ramushu, P.; Matsebatlela, T.; Aderibigbe, B.A. Synthesis of ester-linked ursolic acid-based hybrid compounds: Potential antibacterial and anticancer agents. Chem. Biodivers., 2023, 20(4), e202300034.
[http://dx.doi.org/10.1002/cbdv.202300034] [PMID: 36920086]

Yang, P.; Luo, J-B.; Zhang, L-L.; Wang, Y-S.; Xie, X-B.; Shi, Q-S.; Zhang, X-G. Design, synthesis and antibacterial studies of 1,3,4-oxadiazole-fluoroquinolone hybrids and their molecular docking studies. ChemistrySelect, 2021, 6(46), 13209-13214.
[http://dx.doi.org/10.1002/slct.202103078]

Xu, Z.; Zhao, S.J.; Lv, Z.S.; Gao, F.; Wang, Y.; Zhang, F.; Bai, L.; Deng, J.L. Fluoroquinolone-isatin hybrids and their biological activities. Eur. J. Med. Chem., 2019, 162, 396-406.
[http://dx.doi.org/10.1016/j.ejmech.2018.11.032] [PMID: 30453247]

Shi, Z.; Li, Y.; Kang, Y.; Hu, G.; Huang-Fu, C.; Deng, J.; Liu, B. Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Acta Pharmacol. Sin., 2012, 33(2), 271-278.
[http://dx.doi.org/10.1038/aps.2011.158] [PMID: 22301863]

Chellan, P.; Sadler, P.J. Enhancing the activity of drugs by conjugation to organometallic fragments. Chemistry, 2020, 26(40), 8676-8688.
[http://dx.doi.org/10.1002/chem.201904699] [PMID: 32452579]

Hryhoriv, H.; Kovalenko, S.M.; Georgiyants, M.; Sidorenko, L.; Georgiyants, V. A comprehensive review on chemical synthesis and chemotherapeutic potential of 3-heteroaryl fluoroquinolone Hybrids. Antibiotics, 2023, 12(3), 625.
[http://dx.doi.org/10.3390/antibiotics12030625] [PMID: 36978492]

Swedan, H.K.; Kassab, A.E.; Gedawy, E.M.; Elmeligie, S.E. Topoisomerase II inhibitors design: Early studies and new perspectives. Bioorg. Chem., 2023, 136, 106548.
[http://dx.doi.org/10.1016/j.bioorg.2023.106548] [PMID: 37094479]

Ezelarab, H.A.A.; Hassan, H.A.; Abuo-Rahma, G.E.D.A.; Abbas, S.H. Design, synthesis, and biological investigation of quinoline/ciprofloxacin hybrids as antimicrobial and anti-proliferative agents. J. Indian Chem. Soc., 2023, 20(3), 683-700.
[http://dx.doi.org/10.1007/s13738-022-02704-7]

Abdel-Aal, M.A.A.; Shaykoon, M.S.A.; Abuo-Rahma, G.E.D.A.A.; Mohamed, M.F.A.; Badr, M.; Abdel-Aziz, S.A. Synthesis, antitumor, antibacterial and urease inhibitory evaluation of new piperazinyl N-4 carbamoyl functionalized ciprofloxacin derivatives. Pharmacol. Rep., 2021, 73(3), 891-906.
[http://dx.doi.org/10.1007/s43440-020-00193-0] [PMID: 33389728]

Eisa, M.; Fathy, M.; Abuo-Rahma, G.; Abdel-Aziz, M.; Nazmy, M.; Nazmy, M.H. Anti-proliferative and pro-apoptotic activities of synthesized 3,4,5 tri-methoxy ciprofloxacin chalcone hybrid, through p53 Up-regulation in HepG2 and MCF7 cell lines. Asian Pac. J. Cancer Prev., 2021, 22(10), 3393-3404.
[http://dx.doi.org/10.31557/APJCP.2021.22.10.3393] [PMID: 34711017]

Mohammed, H.H.H.; Abbas, S.H.; Hayallah, A.M.; Abuo-Rahma, G.E.D.A.; Mostafa, Y.A. Novel urea linked ciprofloxacin-chalcone hybrids having antiproliferative topoisomerases I/II inhibitory activities and caspases-mediated apoptosis. Bioorg. Chem., 2021, 106, 104422.
[http://dx.doi.org/10.1016/j.bioorg.2020.104422] [PMID: 33248713]

Fathy, M.; Sun, S.; Zhao, Q.L.; Abdel-Aziz, M.; Abuo-Rahma, G.E.D.A.; Awale, S.; Nikaido, T. A new ciprofloxacin-derivative inhibits proliferation and suppresses the migration ability of hela cells. Anticancer Res., 2020, 40(9), 5025-5033.
[http://dx.doi.org/10.21873/anticanres.14505] [PMID: 32878790]

Mohammed, H.H.H.; Abd El-Hafeez, A.A.; Ebeid, K.; Mekkawy, A.I.; Abourehab, M.A.S.; Wafa, E.I.; Alhaj-Suliman, S.O.; Salem, A.K.; Ghosh, P.; Abuo-Rahma, G.E.D.A.; Hayallah, A.M.; Abbas, S.H. New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. J. Enzyme Inhib. Med. Chem., 2022, 37(1), 1346-1363.
[http://dx.doi.org/10.1080/14756366.2022.2072308] [PMID: 35548854]

Sabet, S. Chalcones: Promising therapeutic agents targeting key players and signalling pathways regulating the hallmarks of cancer. Chem. Biol. Interact., 2023, 369, 110297.
[http://dx.doi.org/10.1016/j.cbi.2022.110297] [PMID: 36496109]

Leite, F.F.; de Sousa, N.F.; de Oliveira, B.H.M.; Duarte, G.D.; Ferreira, M.D.L.; Scotti, M.T.; Filho, J.M.B.; Rodrigues, L.C.; de Moura, R.O.; Mendonça-Junior, F.J.B.; Scotti, L. Anticancer activity of chalcones and its derivatives: Review and in silico studies. Molecules, 2023, 28(10), 4009.
[http://dx.doi.org/10.3390/molecules28104009] [PMID: 37241750]

Akhtar, R.; Noreen, R.; Raza, Z.; Rasul, A.; Zahoor, A.F. Synthesis, anticancer evaluation, and in silico modeling study of some N-acylated ciprofloxacin derivatives. Russ. J. Org. Chem., 2022, 58(4), 541-548.
[http://dx.doi.org/10.1134/S107042802204011X]

Chrzanowska, A.; Struga, M.; Roszkowski, P.; Koliński, M.; Kmiecik, S.; Jałbrzykowska, K.; Zabost, A.; Stefańska, J.; Augustynowicz-Kopeć, E.; Wrzosek, M. The effect of conjugation of ciprofloxacin and moxifloxacin with fatty acids on their antibacterial and anticancer activity. Int. J. Mol. Sci., 2022, 23, 6261.
[http://dx.doi.org/10.3390/ijms23116261] [PMID: 35682940]

Chrzanowska, A.; Roszkowski, P.; Bielenica, A.; Olejarz, W.; Stępień, K.; Struga, M. Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates. Eur. J. Med. Chem., 2020, 185, 111810.
[http://dx.doi.org/10.1016/j.ejmech.2019.111810] [PMID: 31678743]

Chrzanowska, A.; Olejarz, W.; Kubiak-Tomaszewska, G.; Ciechanowicz, A.K.; Struga, M. The effect of fatty acids on ciprofloxacin cytotoxic activity in prostate cancer cell lines-does lipid component enhance anticancer ciprofloxacin potential? Cancers, 2022, 14(2), 409.
[http://dx.doi.org/10.3390/cancers14020409] [PMID: 35053570]

Shahbazi, A.; Mostafavi, H.; Zarrini, G.; Mahdavi, M. Novel N-4-piperazinyl ciprofloxacin-ester hybrids: Synthesis, biological evaluation, and molecular docking studies. Russ. J. Gen. Chem., 2020, 90(8), 1558-1565.
[http://dx.doi.org/10.1134/S1070363220080265]

Szostek, T.; Szulczyk, D.; Szymańska-Majchrzak, J.; Koliński, M.; Kmiecik, S.; Otto-Ślusarczyk, D.; Zawodnik, A.; Rajkowska, E.; Chaniewicz, K.; Struga, M.; Roszkowski, P. Design and synthesis of menthol and thymol derived ciprofloxacin: Influence of structural modifications on the antibacterial activity and anticancer properties. Int. J. Mol. Sci., 2022, 23(12), 6600.
[http://dx.doi.org/10.3390/ijms23126600] [PMID: 35743043]

Samir, M.; Ramadan, M.; Abdelrahman, M.H.; Abdelbaset, M.S.; Abourehab, M.A.S.; Abdel-Aziz, M.; Abuo-Rahma, G.E.D.A. 3,7-bis-benzylidene hydrazide ciprofloxacin derivatives as promising antiproliferative dual TOP I & TOP II isomerases inhibitors. Bioorg. Chem., 2021, 110, 104698.
[http://dx.doi.org/10.1016/j.bioorg.2021.104698] [PMID: 33676043]

Al-Kelaby, K.K.A.; Naser, N.H. Antineoplastic effect of sulfanilamide hybridized with ciprofloxacin ‘in vitro study. Syst. Rev. Pharm., 2020, 11, 157-164.

Swedan, H.K.; Kassab, A.E.; Gedawy, E.M.; Elmeligie, S.E. Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme. J. Enzyme Inhib. Med. Chem., 2023, 38(1), 118-137.
[http://dx.doi.org/10.1080/14756366.2022.2136172] [PMID: 36305290]

Fallica, A.N.; Barbaraci, C.; Amata, E.; Pasquinucci, L.; Turnaturi, R.; Dichiara, M.; Intagliata, S.; Gariboldi, M.B.; Marras, E.; Orlandi, V.T.; Ferroni, C.; Martini, C.; Rescifina, A.; Gentile, D.; Varchi, G.; Marrazzo, A. Nitric oxide photo-donor hybrids of ciprofloxacin and norfloxacin: A shift in activity from antimicrobial to anticancer agents. J. Med. Chem., 2021, 64(15), 11597-11613.
[http://dx.doi.org/10.1021/acs.jmedchem.1c00917] [PMID: 34319100]

Struga, M.; Roszkowski, P.; Bielenica, A.; Otto-Ślusarczyk, D.; Stępień, K.; Stefańska, J.; Zabost, A.; Augustynowicz-Kopeć, E.; Koliński, M.; Kmiecik, S.; Myslovska, A.; Wrzosek, M. N-acylated ciprofloxacin derivatives: Synthesis and in vitro biological evaluation as antibacterial and anticancer agents. ACS Omega, 2023, 8(21), 18663-18684.
[http://dx.doi.org/10.1021/acsomega.3c00554] [PMID: 37273589]

Fawzy, M.A.; Abu-baih, R.H.; Abuo-Rahma, G.E.D.A.; Abdel-Rahman, I.M.; El-Sheikh, A.A.K.; Nazmy, M.H. in vitro anticancer activity of novel ciprofloxacin mannich base in lung adenocarcinoma and high-grade serous ovarian cancer cell lines via attenuating mapk signaling pathway. Molecules, 2023, 28(3), 1137.
[http://dx.doi.org/10.3390/molecules28031137] [PMID: 36770806]

Alaaeldin, R.; Nazmy, M.H.; Abdel-Aziz, M.; Abuo-Rahma, G.E.D.A.; Fathy, M. Cell cycle arrest and apoptotic effect of 7-(4-(n-substituted carbamoylmethyl) piperazin-1-yl) ciprofloxacin-derivative on HCT 116 and A549 cancer cells. Anticancer Res., 2020, 40(5), 2739-2749.
[http://dx.doi.org/10.21873/anticanres.14245] [PMID: 32366419]

Pashapour, N.M.; Dehghan-Nayeri, M.J.; Babaei, E.; Khalaj-Kondori, M.; Mahdavi, M. The assessment of cytotoxicity, apoptosis-inducing activity and molecular docking of a new ciprofloxacin derivative in human leukemic cells. J. Fluoresc., 2023.

Ptaszyńska, N.; Gucwa, K.; Olkiewicz, K.; Heldt, M.; Serocki, M.; Stupak, A.; Martynow, D.; Dębowski, D.; Gitlin-Domagalska, A.; Lica, J.; Łęgowska, A.; Milewski, S.; Rolka, K. Conjugates of ciprofloxacin and levofloxacin with cell-penetrating peptide exhibit antifungal activity and mammalian cytotoxicity. Int. J. Mol. Sci., 2020, 21(13), 4696.
[http://dx.doi.org/10.3390/ijms21134696] [PMID: 32630159]

Shokrzadeh, M.; Mirzaei, H.; Pendarnejad, H.M.; Emami, S. Chromanone oxime analogs of quinolone drugs as cytotoxic agents: in vitro cytotoxicity evaluation and in silico study. Biointerface Res. Appl. Chem., 2023, 13, 1-11.

Arshad, M.; Khan, M.S.; Nami, S.A.A. Norfloxacin analogues: Drug likeness, synthesis, biological, and molecular docking assessment. Russ. J. Bioorganic Chem., 2021, 47(2), 483-495.
[http://dx.doi.org/10.1134/S1068162021020047]

Wang, J.; Tsao, A.; Liu, X. Class of quinolone heterocyclic aromatic molecules for cancer treatment. U.S. Patent 10,202,357, 2019.

Ayati, A.; Moghimi, S.; Salarinejad, S.; Safavi, M.; Pouramiri, B.; Foroumadi, A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem., 2020, 99, 103811.
[http://dx.doi.org/10.1016/j.bioorg.2020.103811] [PMID: 32278207]

Kang, J.J.; Ko, A.; Kil, S.H.; Mallen-St Clair, J.; Shin, D.S.; Wang, M.B.; Srivatsan, E.S. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochim. Biophys. Acta Rev. Cancer, 2023, 1878(1), 188827.
[http://dx.doi.org/10.1016/j.bbcan.2022.188827] [PMID: 36309124]

Bertotti, A.; Papp, E.; Jones, S.; Adleff, V.; Anagnostou, V.; Lupo, B.; Sausen, M.; Phallen, J.; Hruban, C.A.; Tokheim, C.; Niknafs, N.; Nesselbush, M.; Lytle, K.; Sassi, F.; Cottino, F.; Migliardi, G.; Zanella, E.R.; Ribero, D.; Russolillo, N.; Mellano, A.; Muratore, A.; Paraluppi, G.; Salizzoni, M.; Marsoni, S.; Kragh, M.; Lantto, J.; Cassingena, A.; Li, Q.K.; Karchin, R.; Scharpf, R.; Sartore-Bianchi, A.; Siena, S.; Diaz, L.A., Jr; Trusolino, L.; Velculescu, V.E. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 2015, 526(7572), 263-267.
[http://dx.doi.org/10.1038/nature14969] [PMID: 26416732]

Yang, C.H.; Chou, H.C.; Fu, Y.N.; Yeh, C.L.; Cheng, H.W.; Chang, I.C.; Liu, K.J.; Chang, G.C.; Tsai, T.F.; Tsai, S.F.; Liu, H.P.; Wu, Y.C.; Chen, Y.T.; Huang, S.F.; Chen, Y.R. EGFR over- expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim. Biophys. Acta Mol. Basis Dis., 2015, 1852(7), 1540-1549.
[http://dx.doi.org/10.1016/j.bbadis.2015.04.020] [PMID: 25912735]

Kuo, S.C.; Teng, C.M.; Lee, K.H.; Huang, L.J.; Chou, L.C.; Chang, C.S.; Sun, C.M.; Wu, T.S.; Pan, S.L.; Way, T.D.; Lee, J.C. 2-Phenyl-4-quinolones as anticancer agents. U.S. Patent 9,029,394, 2015.

Kuo, S.C.; Teng, C.M.; Lee, K.H.; Huang, L.J.; Chou, L.C.; Chang, C.S.; Sun, C.M.; Wu, T.S.; Pan, S.L.; Way, T.D.; Lee, J.C. 2-selenophene-4-quinolones as anticancer agents. U.S. Patent 9,023,866, 2015.

Kuo, S.C.; Teng, C.M.; Lee, K.H.; Huang, L.J.; Chou, L.C.; Chang, C.S.; Sun, C.M.; Wu, T.S.; Pan, S.L.; Way, T.D.; Lee, J.C. Hydrophilic derivatives of 2-Aryl-4-quinolones as anticancer agents. U.S. Patent 8,440,692, 2013.

Beberok, A.; Rzepka, Z.; Respondek, M.; Rok, J.; Sierotowicz, D.; Wrześniok, D. GSH depletion, mitochondrial membrane breakdown, caspase-3/7 activation and DNA fragmentation in U87MG glioblastoma cells: New insight into the mechanism of cytotoxicity induced by fluoroquinolones. Eur. J. Pharmacol., 2018, 835, 94-107.
[http://dx.doi.org/10.1016/j.ejphar.2018.08.002] [PMID: 30086267]

Beberok, A.; Wrześniok, D.; Rok, J.; Rzepka, Z.; Respondek, M.; Buszman, E. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int. J. Oncol., 2018, 52(5), 1727-1737.
[http://dx.doi.org/10.3892/ijo.2018.4310] [PMID: 29532860]

Pessina, A.; Bonomi, A.; Casati, S.; Collotta, A.; Croera, C.; Marafante, E.; Palitti, F.; Gribaldo, L. Mitochondrial function, apoptosis and cell cycle delay in the WEHI-3B leukaemia cell line and its variant Ciprofloxacin-resistant WEHI-3B/CPX. Cell Prolif., 2007, 40(4), 568-579.
[http://dx.doi.org/10.1111/j.1365-2184.2007.00456.x] [PMID: 17635523]

Kowalski, M.; Gurtowska, N.; Nowak, M.; Joachimiak, R.; Bajek, A.; Olkowska, J.; Drewa, T. The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro. Acta Phys. Pol. B, 2011, 42(3), 859-865.
[http://dx.doi.org/10.5506/APhysPolB.42.859] [PMID: 22125950]

Beberok, A.; Wrześniok, D.; Minecka, A.; Rok, J.; Delijewski, M.; Rzepka, Z.; Respondek, M.; Buszman, E. Ciprofloxacin-mediated induction of S-phase cell cycle arrest and apoptosis in COLO829 melanoma cells. Pharmacol. Rep., 2018, 70(1), 6-13.
[http://dx.doi.org/10.1016/j.pharep.2017.07.007] [PMID: 29306115]

Kloskowski, T.; Gurtowska, N.; Olkowska, J.; Nowak, J.M.; Adamowicz, J.; Tworkiewicz, J.; Dębski, R.; Grzanka, A.; Drewa, T. Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC. Int. J. Oncol., 2012, 41(6), 1943-1949.
[http://dx.doi.org/10.3892/ijo.2012.1653] [PMID: 23042104]

Yadav, V.; Varshney, P.; Sultana, S.; Yadav, J.; Saini, N. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer, 2015, 15(1), 581.
[http://dx.doi.org/10.1186/s12885-015-1560-y] [PMID: 26260159]

Gürbay, A.; Osman, M.; Favier, A.; Hincal, F. Ciprofloxacin-induced cytotoxicity and apoptosis in hela cells. Toxicol. Mech. Methods, 2005, 15(5), 339-342.
[http://dx.doi.org/10.1080/153765291009877] [PMID: 20021053]

Perucca, P.; Savio, M.; Cazzalini, O.; Mocchi, R.; Maccario, C.; Sommatis, S.; Ferraro, D.; Pizzala, R.; Pretali, L.; Fasani, E.; Albini, A.; Stivala, L.A. Structure-activity relationship and role of oxygen in the potential antitumour activity of fluoroquinolones in human epithelial cancer cells. J. Photochem. Photobiol. B, 2014, 140, 57-68.
[http://dx.doi.org/10.1016/j.jphotobiol.2014.07.006] [PMID: 25105482]

Davary Avareshk, A.; Jalal, R.; Gholami, J. The effect of ciprofloxacin on doxorubicin cytotoxic activity in the acquired resistance to doxorubicin in DU145 prostate carcinoma cells. Med. Oncol., 2022, 39(12), 194.
[http://dx.doi.org/10.1007/s12032-022-01787-9] [PMID: 36071289]

Kloskowski, T.; Gurtowska, N.; Bajek, A.; Drewa, T. Ciprofloxacin as a prophylactic agent against prostate cancer: A “two hit” hypothesis. Med. Hypotheses, 2012, 78(2), 235-238.
[http://dx.doi.org/10.1016/j.mehy.2011.10.034] [PMID: 22098728]

Herold, C.; Ocker, M.; Ganslmayer, M.; Gerauer, H.; Hahn, E.G. ; Schuppan, D. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br. J. Cancer, 2002, 86(3), 443-448.
[http://dx.doi.org/10.1038/sj.bjc.6600079] [PMID: 11875713]

Jemel-Oualha, I.; Elloumi-Mseddi, J.; Beji, A.; Hakim, B.; Aifa, S. Controversial effect on Erk activation of some cytotoxic drugs in human LOVO colon cancer cells. J. Recept. Signal Transduct. Res., 2016, 36(1), 21-25.
[http://dx.doi.org/10.3109/10799893.2014.975246] [PMID: 25343691]

Bourikas, L.A.; Kolios, G.; Valatas, V.; Notas, G.; Drygiannakis, I.; Pelagiadis, I.; Manousou, P.; Klironomos, S.; Mouzas, I.A.; Kouroumalis, E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-β1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br. J. Pharmacol., 2009, 157(3), 362-370.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00161.x] [PMID: 19371339]

Herold, C.; Ganslmayer, M.; Ocker, M.; Blauberger, S.; Zopf, S.; Hahn, E.; Schuppan, D. Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int. J. Oncol., 2003, 23(3), 751-756.
[http://dx.doi.org/10.3892/ijo.23.3.751] [PMID: 12888913]

Aranha, O.; Zhu, L.; Alhasan, S.; Wood, D.P., Jr; Kuo, T.H.; Sarkar, F.H. Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cells. J. Urol., 2002, 167(3), 1288-1294.
[http://dx.doi.org/10.1016/S0022-5347(05)65283-4] [PMID: 11832715]

Aranha, O.; Wood, D.P., Jr; Sarkar, F.H. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin. Cancer Res., 2000, 6(3), 891-900.
[PMID: 10741713]

Kamat, A.M.; DeHaven, J.I.; Lamm, D.L. Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer. Urology, 1999, 54(1), 56-61.
[http://dx.doi.org/10.1016/S0090-4295(99)00064-3] [PMID: 10414727]

Kloskowski, T.; Olkowska, J.; Nazlica, A.; Drewa, T. The influence of ciprofloxacin on hamster ovarian cancer cell line CHO AA8. Acta Pol. Pharm., 2010, 67(4), 345-349.
[PMID: 20635529]

Engeler, D.S.; Scandella, E.; Ludewig, B.; Schmid, H.P. Ciprofloxacin and epirubicin synergistically induce apoptosis in human urothelial cancer cell lines. Urol. Int., 2012, 88(3), 343-349.
[http://dx.doi.org/10.1159/000336130] [PMID: 22378292]

Mondal, E.R.; Das, S.K.; Mukherjee, P. Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac. J. Cancer Prev., 2004, 5(2), 196-204.
[PMID: 15244525]

Kim, K.; Khang, D. Past, present, and future of anticancer nanomedicine. Int. J. Nanomedicine, 2020, 15, 5719-5743.
[http://dx.doi.org/10.2147/IJN.S254774] [PMID: 32821098]

Kim, J.; Cho, H.; Lim, D.K.; Joo, M.K.; Kim, K. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int. J. Mol. Sci., 2023, 24(12), 10082.
[http://dx.doi.org/10.3390/ijms241210082] [PMID: 37373227]

Kasi, P.B.; Mallela, V.R.; Ambrozkiewicz, F.; Trailin, A.; Liška, V.; Hemminki, K. Theranostics nanomedicine applications for colorectal cancer and metastasis: Recent advances. Int. J. Mol. Sci., 2023, 24(9), 7922.
[http://dx.doi.org/10.3390/ijms24097922] [PMID: 37175627]

Das, C.G.A.; Kumar, V.G.; Dhas, T.S.; Karthick, V.; Kumar, C.M.V. Nanomaterials in anticancer applications and their mechanism of action - A review. Nanomed. Nanotechnol. Biol. Med., 2023, 2023(47), 102613.

Aalhate, M.; Mahajan, S.; Singh, H.; Guru, S.K.; Singh, P.K. Nanomedicine in therapeutic warfront against estrogen receptor- positive breast cancer. Drug Deliv. Transl. Res., 2023, 13(6), 1621-1653.
[http://dx.doi.org/10.1007/s13346-023-01299-7] [PMID: 36795198]

Algethami, F.K.; Elamin, M.R.; Abdulkhair, B.Y.; Al-Zharani, M.; Qarah, N.A.S.; Alghamdi, M.A. Fast fabrication of bismuth oxyiodide/carbon-nanofibers composites for efficient anti-proliferation of liver and breast cancer cells. Z. Anorg. Allg. Chem., 2021, 647(19), 1921-1929.
[http://dx.doi.org/10.1002/zaac.202100205]

Ababneh, R.; Smadi, M.; Bensiradj, N.E.H.; Al-Akhras, M.A.; Al-Hiari, Y.; Jum’h, I.; Abu-Dahab, R.; Al Bataineh, Q.M.; Telfah, A. UV-Vis, FTIR and DFT studies of the fluoroquinolone [Pyrido Pyrolo Quinoxaline (PPQ)] tethered to gold nanoparticles as a novel anticancer. J. Inorg. Organomet. Polym. Mater., 2023, 33(6), 1646-1656.
[http://dx.doi.org/10.1007/s10904-023-02596-x]